
|Videos|May 4, 2020
Biologic use in the era of COVID-19
Author(s)Jessica Barry
This week, we spoke with Mark Lebwohl, M.D., about his recent article featured in the Journal of the American Academy of Dermatology regarding biologic use in dermatology patients during the COVID-19 pandemic.
Advertisement
This week, we spoke with Mark Lebwohl, M.D., Waldman Professor and Chair, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, about his recent article featured in the Journal of the American Academy of Dermatology regarding biologic use in dermatology patients during the COVID-19 pandemic.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AAD Pediatric AD Guidelines Back Roflumilast, Ruxolitinib, Tapinarof
2
Modern Psoriasis Treatment: From Topicals to IL-23 and IL-17 Biologics
3
ICYMI: EU Approves Upadacitinib for Severe Alopecia as US Review Remains Pending
4
Interim Trial Results and Preclinical Data Highlight Potential of ABS-201 in Androgenetic Alopecia
5









